BlackRock, Inc. 13D and 13G filings for Karyopharm Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-07-08 4:32 pm Sale | 2024-06-30 | 13G | Karyopharm Therapeutics Inc. KPTI | BlackRock Inc. BLK | 277,986 3.500% | -393,459 (-58.60%) | Filing |
| 2024-01-25 1:48 pm Purchase | 2023-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI | BlackRock Inc. BLK | 671,445 8.800% | 104,229 (+18.38%) | Filing |
| 2023-01-26 08:52 am Unchanged | 2022-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI | BlackRock Inc. BLK | 567,216 10.500% | 0 (Unchanged) | Filing |
| 2023-01-20 5:17 pm Sale | 2022-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI | BlackRock Inc. BLK | 567,216 10.500% | -27,331 (-4.60%) | Filing |
| 2022-01-27 5:13 pm Unchanged | 2021-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI | BlackRock Inc. BLK | 594,547 11.800% | 0 (Unchanged) | Filing |
| 2022-01-26 09:16 am Purchase | 2021-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI | BlackRock Inc. BLK | 594,547 11.800% | 96,207 (+19.31%) | Filing |
| 2021-01-26 6:52 pm Purchase | 2020-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI | BlackRock Inc. BLK | 498,340 10.200% | 4,086 (+0.83%) | Filing |
| 2020-12-08 4:56 pm Purchase | 2020-11-30 | 13G | Karyopharm Therapeutics Inc. KPTI | BlackRock Inc. BLK | 494,254 10.100% | 176,325 (+55.46%) | Filing |